Disrupting Protein–Protein Interfaces Using GRID Molecular Interaction Fields

[1]  Anil Kumar Tripathi,et al.  Exploring Problems and Solutions in estimating Testing Effort for Non Functional Requirement. , 2012, BIOINFORMATICS 2012.

[2]  Laurie E. Grove,et al.  Structural conservation of druggable hot spots in protein–protein interfaces , 2011, Proceedings of the National Academy of Sciences.

[3]  Holger Gohlke,et al.  Predicting protein-protein interactions with DrugScorePPI: fully-flexible docking, scoring, and in silico alanine-scanning , 2011, J. Cheminformatics.

[4]  C. Rudin,et al.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Daniel W. A. Buchan,et al.  Predictions of Hot Spot Residues at Protein-Protein Interfaces Using Support Vector Machines , 2011, PloS one.

[6]  Paolo Benedetti,et al.  FLAP: GRID Molecular Interaction Fields in Virtual Screening. Validation using the DUD Data Set , 2010, J. Chem. Inf. Model..

[7]  Chong Li,et al.  D-peptide inhibitors of the p53–MDM2 interaction for targeted molecular therapy of malignant neoplasms , 2010, Proceedings of the National Academy of Sciences.

[8]  Holger Gohlke,et al.  DrugScorePPI webserver: fast and accurate in silico alanine scanning for scoring protein–protein interactions , 2010, Nucleic Acids Res..

[9]  Chong Li,et al.  A left-handed solution to peptide inhibition of the p53-MDM2 interaction. , 2010, Angewandte Chemie.

[10]  Wei Wang,et al.  Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery , 2010, Cell cycle.

[11]  Stefano Alcaro,et al.  Computational analysis of Human Immunodeficiency Virus (HIV) Type-1 reverse transcriptase crystallographic models based on significant conserved residues found in Highly Active Antiretroviral Therapy (HAART)-treated patients. , 2010, Current medicinal chemistry.

[12]  Gabriele Cruciani,et al.  Molecular fields in drug discovery: getting old or reaching maturity? , 2010, Drug discovery today.

[13]  Xing-Ming Zhao,et al.  APIS: accurate prediction of hot spots in protein interfaces by combining protrusion index with solvent accessibility , 2010, BMC Bioinformatics.

[14]  Andrew J. Wilson,et al.  Inhibition of protein-protein interactions using designed molecules. , 2009, Chemical Society reviews.

[15]  Chong Li,et al.  Apamin as a template for structure-based rational design of potent peptide activators of p53. , 2009, Angewandte Chemie.

[16]  Alicia P. Higueruelo,et al.  Atomic Interactions and Profile of Small Molecules Disrupting Protein–Protein Interfaces: the TIMBAL Database , 2009, Chemical biology & drug design.

[17]  Massimiliano Pontil,et al.  Prediction of hot spot residues at protein-protein interfaces by combining machine learning and energy-based methods , 2009, BMC Bioinformatics.

[18]  M. Bolognesi,et al.  Structural basis for bivalent Smac-mimetics recognition in the IAP protein family. , 2009, Journal of molecular biology.

[19]  S. Hymowitz,et al.  Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. , 2009, ACS chemical biology.

[20]  Ozlem Keskin,et al.  Identification of computational hot spots in protein interfaces: combining solvent accessibility and inter-residue potentials improves the accuracy , 2009, Bioinform..

[21]  G. Dubin,et al.  High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx , 2009, Cell cycle.

[22]  A. Dömling.  Hot, hotter, hottest , 2009, Cell cycle.

[23]  Chong Li,et al.  Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.

[24]  Doheon Lee,et al.  A feature-based approach to modeling protein–protein interaction hot spots , 2009, Nucleic acids research.

[25]  Dima Kozakov,et al.  Fragment-based identification of druggable 'hot spots' of proteins using Fourier domain correlation techniques , 2009, Bioinform..

[26]  Jinyan Li,et al.  ‘Double water exclusion’: a hypothesis refining the O-ring theory for the hot spots at protein interfaces , 2009, Bioinform..

[27]  M. Bolognesi,et al.  Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. , 2009, Biochemical and biophysical research communications.

[28]  Carlo Scolastico,et al.  Targeting the X-linked inhibitor of apoptosis protein through 4-substituted azabicyclo[5.3.0]alkane smac mimetics. Structure, activity, and recognition principles. , 2008, Journal of molecular biology.

[29]  Su Qiu,et al.  Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). , 2008, Journal of medicinal chemistry.

[30]  Shaomeng Wang,et al.  Interaction of a cyclic, bivalent smac mimetic with the x-linked inhibitor of apoptosis protein. , 2008, Biochemistry.

[31]  Julie C. Mitchell,et al.  KFC Server: interactive forecasting of protein interaction hot spots , 2008, Nucleic Acids Res..

[32]  Luis A Nunes Amaral.  A truer measure of our ignorance , 2008, Proceedings of the National Academy of Sciences.

[33]  Hyeong Jun An,et al.  Estimating the size of the human interactome , 2008, Proceedings of the National Academy of Sciences.

[34]  Ozlem Keskin,et al.  HotSprint: database of computational hot spots in protein interfaces , 2007, Nucleic Acids Res..

[35]  Gary D Bader,et al.  Computational Prediction of Protein–Protein Interactions , 2008, Molecular biotechnology.

[36]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[37]  Loriano Storchi,et al.  New and Original pKa Prediction Method Using Grid Molecular Interaction Fields , 2007, J. Chem. Inf. Model..

[38]  Julie C. Mitchell,et al.  An automated decision‐tree approach to predicting protein interaction hot spots , 2007, Proteins.

[39]  Pedro A Fernandes,et al.  Hot spots—A review of the protein–protein interface determinant amino‐acid residues , 2007, Proteins.

[40]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[41]  Burkhard Rost,et al.  Protein–Protein Interaction Hotspots Carved into Sequences , 2007, PLoS Comput. Biol..

[42]  Anna Linusson,et al.  SHOP: scaffold HOPping by GRID-based similarity searches. , 2007, Journal of medicinal chemistry.

[43]  Yigong Shi,et al.  Structure-activity based study of the Smac-binding pocket within the BIR3 domain of XIAP. , 2007, Bioorganic & medicinal chemistry.

[44]  Sandor Vajda,et al.  Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. , 2007, Journal of medicinal chemistry.

[45]  Gabriele Cruciani,et al.  A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands And Proteins (FLAP): Theory and Application , 2007, J. Chem. Inf. Model..

[46]  J. Irwin,et al.  Benchmarking sets for molecular docking. , 2006, Journal of medicinal chemistry.

[47]  C. Schubert,et al.  Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2. , 2006, Journal of the American Chemical Society.

[48]  B. Cosimelli,et al.  Calcium channel antagonists discovered by a multidisciplinary approach. , 2006, Journal of medicinal chemistry.

[49]  Stefano Alcaro,et al.  GBPM: GRID-based pharmacophore model: concept and application studies to protein-protein recognition , 2006, Bioinform..

[50]  A. Levine,et al.  The P53 pathway: what questions remain to be explored? , 2006, Cell Death and Differentiation.

[51]  T. Fox.  Protein Selectivity Studies Using GRID‐MIFs , 2006 .

[52]  Rebecca C. Wade.  Calculation and Application of Molecular Interaction Fields , 2006 .

[53]  Peter Goodford,et al.  The Basic Principles of GRID , 2006 .

[54]  Oliver Zerbe,et al.  Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction , 2006 .

[55]  G. Cruciani,et al.  MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. , 2005, Journal of medicinal chemistry.

[56]  A. Hamilton,et al.  Strategies for targeting protein-protein interactions with synthetic agents. , 2005, Angewandte Chemie.

[57]  François Stricher,et al.  The FoldX web server: an online force field , 2005, Nucleic Acids Res..

[58]  K. Christopher Garcia,et al.  The Structure of Interleukin-2 Complexed with Its Alpha Receptor , 2005, Science.

[59]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[60]  Maxwell D Cummings,et al.  Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. , 2005, Journal of medicinal chemistry.

[61]  David C Fry,et al.  NMR structure of a complex between MDM2 and a small molecule inhibitor , 2004, Journal of biomolecular NMR.

[62]  Saul H Rosenberg,et al.  Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. , 2004, Journal of medicinal chemistry.

[63]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[64]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[65]  M. Randal,et al.  Potent small-molecule binding to a dynamic hot spot on IL-2. , 2003, Journal of the American Chemical Society.

[66]  D. Bailey,et al.  The Binding Interface Database (BID): A Compilation of Amino Acid Hot Spots in Protein Interfaces , 2003, Bioinform..

[67]  Sandor Vajda,et al.  CAPRI: A Critical Assessment of PRedicted Interactions , 2003, Proteins.

[68]  B. Rost,et al.  Predicted protein–protein interaction sites from local sequence information , 2003, FEBS letters.

[69]  Michelle R. Arkin,et al.  Binding of small molecules to an adaptive protein–protein interface , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[70]  S. Srinivasula,et al.  Mechanism of XIAP-mediated inhibition of caspase-9. , 2003, Molecular cell.

[71]  B. Rost,et al.  Analysing six types of protein-protein interfaces. , 2003, Journal of molecular biology.

[72]  Samuel K Sia,et al.  Short constrained peptides that inhibit HIV-1 entry , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Serge Muyldermans,et al.  Kinetic and Affinity Predictions of a Protein-Protein Interaction Using Multivariate Experimental Design* , 2002, The Journal of Biological Chemistry.

[74]  Andrew R. Leach,et al.  A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP , 2002, J. Comput. Aided Mol. Des..

[75]  J. Feigon,et al.  Solution structures of UBA domains reveal a conserved hydrophobic surface for protein-protein interactions. , 2002, Journal of molecular biology.

[76]  Sandor Vajda,et al.  Computational mapping identifies the binding sites of organic solvents on proteins , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[77]  P. Toogood.  Inhibition of protein-protein association by small molecules: approaches and progress. , 2002, Journal of medicinal chemistry.

[78]  A. Valencia,et al.  Prediction of protein--protein interaction sites in heterocomplexes with neural networks. , 2002, European journal of biochemistry.

[79]  M. Gerstein,et al.  Relating whole-genome expression data with protein-protein interactions. , 2002, Genome research.

[80]  G. Church,et al.  Correlation between transcriptome and interactome mapping data from Saccharomyces cerevisiae , 2001, Nature Genetics.

[81]  A. Grigoriev.  A relationship between gene expression and protein interactions on the proteome scale: analysis of the bacteriophage T7 and the yeast Saccharomyces cerevisiae. , 2001, Nucleic acids research.

[82]  Huan‐Xiang Zhou,et al.  Prediction of protein interaction sites from sequence profile and residue neighbor list , 2001, Proteins.

[83]  Kurt S. Thorn,et al.  ASEdb: a database of alanine mutations and their effects on the free energy of binding in protein interactions , 2001, Bioinform..

[84]  Geng Wu,et al.  Structural basis of IAP recognition by Smac/DIABLO , 2000, Nature.

[85]  Stephen F. Betz,et al.  Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain , 2000, Nature.

[86]  M Pastor,et al.  VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[87]  A. Thomas,et al.  A fast method to predict protein interaction sites from sequences. , 2000, Journal of molecular biology.

[88]  A G Cochran,et al.  Antagonists of protein-protein interactions. , 2000, Chemistry & biology.

[89]  R. Spencer,et al.  High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. , 1998, Biotechnology and bioengineering.

[90]  A. Bogan,et al.  Anatomy of hot spots in protein interfaces. , 1998, Journal of molecular biology.

[91]  B. Nelson,et al.  Biology of the interleukin-2 receptor. , 1998, Advances in immunology.

[92]  S. Jones,et al.  Prediction of protein-protein interaction sites using patch analysis. , 1997, Journal of molecular biology.

[93]  D. Covell,et al.  A role for surface hydrophobicity in protein‐protein recognition , 1994, Protein science : a publication of the Protein Society.

[94]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[95]  R. M. Burnett,et al.  Distribution and complementarity of hydropathy in mutisunit proteins , 1991, Proteins.

[96]  P. Goodford.  A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. , 1985, Journal of medicinal chemistry.